Thomas DG - Search Results

1

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.

Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH. Schuetze SM, et al. Among authors: thomas dg. JAMA Oncol. 2018 Jun 1;4(6):814-820. doi: 10.1001/jamaoncol.2018.0601. JAMA Oncol. 2018. PMID: 29710216 Free PMC article. Clinical Trial.

2

Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.

Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Thomas DG, et al. Clin Cancer Res. 2002 Mar;8(3):788-93. Clin Cancer Res. 2002. PMID: 11895910

3

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.

Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L. Mace J, et al. Cancer. 2002 Dec 1;95(11):2373-9. doi: 10.1002/cncr.11029. Cancer. 2002. PMID: 12436445 Free article.

4

Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma.

Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, Hollenberg PF, Baker LH. Dhaini HR, et al. Among authors: thomas dg. J Clin Oncol. 2003 Jul 1;21(13):2481-5. doi: 10.1200/JCO.2003.06.015. J Clin Oncol. 2003. PMID: 12829666

5

Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma.

Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Hughes DP, et al. Among authors: thomas dg. Cancer Res. 2004 Mar 15;64(6):2047-53. doi: 10.1158/0008-5472.can-03-3096. Cancer Res. 2004. PMID: 15026342

6

Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.

Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, Yu D, Pollock RE, Baker L. Thomas DG, et al. Cancer. 2005 Feb 15;103(4):830-8. doi: 10.1002/cncr.20847. Cancer. 2005. PMID: 15641030 Free article.

7

Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition.

Hughes DP, Thomas DG, Giordano TJ, McDonagh KT, Baker LH. Hughes DP, et al. Among authors: thomas dg. Pediatr Blood Cancer. 2006 May 1;46(5):614-23. doi: 10.1002/pbc.20454. Pediatr Blood Cancer. 2006. PMID: 16007579 Free article.

8

Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.

McHugh JB, Thomas DG, Herman JM, Ray ME, Baker LH, Adsay NV, Rabah R, Lucas DR. McHugh JB, et al. Among authors: thomas dg. Cancer. 2006 Aug 1;107(3):554-62. doi: 10.1002/cncr.22019. Cancer. 2006. PMID: 16795069 Free article.

9

Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.

Mensah-Osman EJ, Thomas DG, Tabb MM, Larios JM, Hughes DP, Giordano TJ, Lizyness ML, Rae JM, Blumberg B, Hollenberg PF, Baker LH. Mensah-Osman EJ, et al. Among authors: thomas dg. Cancer. 2007 Mar 1;109(5):957-65. doi: 10.1002/cncr.22479. Cancer. 2007. PMID: 17279585 Free PMC article.

10

Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.

Chugh R, Wagner T, Griffith KA, Taylor JM, Thomas DG, Worden FP, Leu KM, Zalupski MM, Baker LH. Chugh R, et al. Among authors: thomas dg. Cancer. 2007 Jun 1;109(11):2315-22. doi: 10.1002/cncr.22669. Cancer. 2007. PMID: 17464949 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

604 results

Search Page